Default company panoramic image

Infarct Reduction Technologies Inc.

Non-invasive disposable device to improve heart attack treatment - reduces heart damage by up to 50% with large cost savings potential

  • Stage Product In Development
  • Industry Medical Devices and Equipment
  • Location Waldwick, NJ, USA
  • Currency USD
  • Founded February 2010
  • Employees 5

Company Summary

IRT is set to capitalize on an important recent discovery that a therapy called “remote ischemic preconditioning” virtually eliminates reperfusion injury. As a result, it reduces heart attack damage by up to 50%. The therapy has been safely applied in over 60 studies on over 10,000 patients. Current manual delivery however limits its adoption. IRT is developing a patented, single-button automatic device to simplify its delivery.


  • Default avatar
    Boris Leschinsky

    Mr. Leschinsky is a seasoned medical device executive with over 25 years of experience in product and business development. Between 2005-2009, he served as CTO of Datascope Corp. (sold in 2009 for $950 mm) following other senior positions at that company since 1990. He has strong business and product development expertise in cardiovascular fields and is a named inventor on 70 patents.

  • Default avatar
    Donald J Southard
    Executive Chairman

    Mr. Southard brings more than 30 years of executive experience, sales and marketing strategies, and a history of building winning companies. Presently a CEO of InfraReDx, he previously served as a CEO of Zonare Medical Systems, where he led the company’s first product launch and grew sales to $50 million. He also held senior leadership positions at Datascope, Toshiba Medical Systems, and Philips Medical Systems.

  • Default avatar
    Mark N Abramovich

    With over 15 years of professional experience, Mr. Abramovich developed the Panályis system for pandemic management. He has worked with over 75 hospitals and has been recognized for his expertise by the CDC. He was a former equity research analyst for Wachovia Securities, a prior Marine Corps Officer and holds a BA from NYU and an MBA from the Wharton School of business.

  • Default avatar
    Abe Abramovich

    Mr. Abramovich has more than 20 years of experience as VP and Manager of Engineering in medical product engineering and technology development, including senior R&D positions at Datascope, Philips, and Dräger. Mr. Abramovich is recognized by his peers as an industry expert. He has 6 patents and is a senior IEEE member. He received his MSEE from Columbia University.

  • Default avatar
    Kirk N Garratt, M.D.
    Medical Director

    Dr. Garratt has 20+ years of experience as practicing interventional cardiologist, over 120 peer-reviewed publications, and international reputation for excellence in clinical research with long-standing interest in AMI management. He is currently the Director of Research, Lenox Hill Hospital in New York City, NY.

  • Default avatar
    William W O'Neill, M.D.
    Principal Investigator for a clinical study

    Dr. O’Neill has over 30 years of experience in cardiology. He is a pioneer in the field of interventional cardiology, and is renowned for excellence in interventional cardiovascular research. He led multiple clinical trials, including seminal studies of myocardial infarction management. He has over 35 published book chapters and 300 peer-reviewed publications. His current position is that of Medical Director, Center for Structural Heart Disease,

Previous Investors

  • Default avatar
    Company has been self-financed by founders